Mallinckrodt (MNK) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales increased 1.7% year-over-year to $505.5 million, driven by Specialty Generics growth and stable Specialty Brands performance.

• Net loss for Q3 was $26.2 million, a significant improvement from $1.72 billion loss in Q3 2023.

• Gross profit margin improved to 43.7% from 30.3% year-over-year, reflecting lower intangible asset amortization and favorable product mix.

• Entered into a $925 million agreement to divest the Therakos business, with proceeds earmarked for debt reduction by over 60%.

• Emerged from Chapter 11 bankruptcy in November 2023, adopting fresh-start accounting and restructuring its board and capital structure.

Financial highlights

• Q3 2024 net sales: $505.5 million (up 1.7% year-over-year); nine months: $1.49 billion (up 6.5%).

• Q3 net loss was $26.2 million; nine-month net loss was $134.9 million, both significantly improved from prior year.

• Q3 Adjusted EBITDA was $160.6 million, down 11.1% year-over-year due to Therakos transaction expenses and increased commercial investment.

• Gross margin improved to 43.7% from 30.3% year-over-year; adjusted gross margin was 65.4% vs. 66.3%.

• Cash and cash equivalents at quarter end were $410.5 million, up from $291 million in Q2.

Outlook and guidance

• Full-year 2024 net sales expected between $1.9 billion and $2 billion.

• Adjusted EBITDA guidance raised to $590–$620 million, reflecting Therakos sale impact and transaction-related expenses.

• Acthar Gel net sales expected to grow approximately 10% year-over-year in 2024.

• Specialty generics segment on track for another year of double-digit net sales growth.

• Guidance reflects removal of Therakos December contribution and $28 million in transaction-related expenses.